Alpa Laboratories per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹1.68₹6.71₹9.34₹8.01₹5.90
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹1.44₹0.00₹9.34₹8.01₹5.90
₹88.53₹88.53₹81.48₹72.20₹63.96
₹52.58₹50.29₹53.45₹51.68₹43.93
—₹4.73₹3.35₹1.73−₹2.30
₹2.85₹2.85−₹2.05−₹1.30−₹2.84
2.12.12.12.12.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALPA₹52.20

Alpa Laboratories Limited

· Pharma & Health
₹ CrorePeersBALPHARMAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹110 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS5.908.019.346.711.68
Diluted EPS5.908.019.340.001.44
Book Value per Share63.9672.2081.4888.5388.53
Revenue per Share43.9351.6853.4550.2952.58
Cash Flow per Share-2.301.733.354.73—
Free Cash Flow per Share-2.84-1.30-2.052.852.85
Shares Outstanding (cr)2.12.12.12.12.1
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.